{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:00:19Z","timestamp":1786546819732,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005825","name":"National Institute of Food and Agriculture","doi-asserted-by":"crossref","award":["2023-38821-39584"],"award-info":[{"award-number":["2023-38821-39584"]}],"id":[{"id":"10.13039\/100005825","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005825","name":"National Institute of Food and Agriculture","doi-asserted-by":"crossref","award":["2023-38821-39584"],"award-info":[{"award-number":["2023-38821-39584"]}],"id":[{"id":"10.13039\/100005825","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kentucky Medical Services Foundation Chair in Pharmacy"},{"DOI":"10.13039\/100019888","name":"University of Kentucky College of Pharmacy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019888","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]},{"name":"George A. Digenis Professorship in Drug Design and Discovery"},{"name":"Center of Biomedical Research Excellence (COBRE) for Translational Chemical Biology","award":["P20GM130456"],"award-info":[{"award-number":["P20GM130456"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000117, UL1TR001998"],"award-info":[{"award-number":["UL1TR000117, UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["R01CA243529"],"award-info":[{"award-number":["R01CA243529"]}]},{"name":"National Cancer Institute","award":["R01CA243529"],"award-info":[{"award-number":["R01CA243529"]}]},{"DOI":"10.13039\/100019888","name":"College of Pharmacy, University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04935-4","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T01:52:22Z","timestamp":1786499542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma"],"prefix":"10.1007","volume":"96","author":[{"given":"Kumar Kulldeep","family":"Niloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazmul Hasan","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas S.","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon S.","family":"Thorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-4533","authenticated-orcid":false,"given":"Markos","family":"Leggas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"7Supplement","key":"4935_CR1","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1158\/1538-7445.Am2026-3504","volume":"86","author":"S Acharya","year":"2026","unstructured":"Acharya S, Yetirajam R, Kazuto Y, Bhosale S, Rohr J, Leggas M (2026) Abstract 3504: Mithramycin analogues trap the EWS-FLI1 transcriptional complex, evict ETV6, and disable oncogenic condensate function in Ewing sarcoma. Cancer Res 86(7Supplement):3504\u20133504. https:\/\/doi.org\/10.1158\/1538-7445.Am2026-3504","journal-title":"Cancer Res"},{"issue":"8_Supplement_1","key":"4935_CR2","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/1538-7445.Am2025-4360","volume":"85","author":"R Yetirajam","year":"2025","unstructured":"Yetirajam R, Acharya S, Niloy KK, Kazuto Y, Horn J, Prisinzano T, Thorson JS, Tsodikov O, Rohr J, Leggas M (2025) Abstract 4360: development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma. Cancer Res 85(8_Supplement_1):4360\u20134360. https:\/\/doi.org\/10.1158\/1538-7445.Am2025-4360","journal-title":"Cancer Res"},{"key":"4935_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060765","author":"KK Niloy","year":"2025","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2025) Preclinical pharmacokinetic evaluation of mithramycin and mithramycin SA tryptophan-conjugated analog. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17060765","journal-title":"Pharmaceutics"},{"key":"4935_CR4","doi-asserted-by":"publisher","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2026) Nonlinear Mixed-Effects Modeling to Characterize the Pharmacokinetics of a Novel Mithramycin Analogue for Ewing Sarcoma in Mice. PREPRINT (Version 1) available at Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-9035594\/v1","DOI":"10.21203\/rs.3.rs-9035594\/v1"},{"key":"4935_CR5","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9400841\/v1","author":"K Niloy","year":"2026","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2026) Bridging tumor growth dynamics and survival in preclinical oncology drug development: a translational tumor growth inhibition and time-to-event (TGI-TTE) modeling framework. Clin Pharmacol Ther.PREPRINT (Version 1) available at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-9400841\/v1","journal-title":"Research Square"},{"issue":"6","key":"4935_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40262-019-00741-9","volume":"58","author":"NA Miller","year":"2019","unstructured":"Miller NA, Reddy MB, Heikkinen AT, Lukacova V, Parrott N (2019) Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. Clin Pharmacokinet 58(6):727\u2013746. https:\/\/doi.org\/10.1007\/s40262-019-00741-9","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4935_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/bdd.2359","volume":"44","author":"J Mao","year":"2023","unstructured":"Mao J, Ma F, Yu J, Bruyn T, Ning M, Bowman C, Chen Y (2023) Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds. Biopharm Drug Dispos 44(4):315\u2013334. https:\/\/doi.org\/10.1002\/bdd.2359","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"4935_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s11095-024-03725-y","volume":"41","author":"Y Li","year":"2024","unstructured":"Li Y, Wang Z, Li Y, Du J, Gao X, Li Y, Lai L (2024) A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans. Pharm Res 41(7):1369\u20131379. https:\/\/doi.org\/10.1007\/s11095-024-03725-y","journal-title":"Pharm Res"},{"issue":"6","key":"4935_CR9","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01138-2","volume":"27","author":"M Le Merdy","year":"2025","unstructured":"Le Merdy M, Tan ML, Lukacova V (2025) Clinical ocular exposure extrapolation for an ophthalmic ointment using PBPK modeling and simulation. AAPS J 27(6):150. https:\/\/doi.org\/10.1208\/s12248-025-01138-2","journal-title":"AAPS J"},{"issue":"1","key":"4935_CR10","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1002\/jcph.2117","volume":"62","author":"A Balhara","year":"2022","unstructured":"Balhara A, Kumar AR, Unadkat JD (2022) Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies. J Clin Pharmacol 62(1):S94\u2013s114. https:\/\/doi.org\/10.1002\/jcph.2117","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4935_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","volume":"80","author":"PJ Grohar","year":"2017","unstructured":"Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC (2017) A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol 80(3):645\u2013652. https:\/\/doi.org\/10.1007\/s00280-017-3382-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"4935_CR12","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1002\/jps.21759","volume":"98","author":"P Poulin","year":"2009","unstructured":"Poulin P, Theil FP (2009) Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98(12):4941\u20134961. https:\/\/doi.org\/10.1002\/jps.21759","journal-title":"J Pharm Sci"},{"issue":"2","key":"4935_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","volume":"64","author":"DW van Valkengoed","year":"2025","unstructured":"van Valkengoed DW, Krekels EHJ, Knibbe CAJ (2025) All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology. Clin Pharmacokinet 64(2):173\u2013192. https:\/\/doi.org\/10.1007\/s40262-024-01444-6","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4935_CR14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","volume":"157","author":"V Sharma","year":"2009","unstructured":"Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157(6):907\u2013921. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00267.x","journal-title":"Br J Pharmacol"},{"issue":"6","key":"4935_CR15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1124\/dmd.118.085605","volume":"47","author":"PB Pierrillas","year":"2019","unstructured":"Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M (2019) Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy. Drug Metab Dispos 47(6):648\u2013656. https:\/\/doi.org\/10.1124\/dmd.118.085605","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"4935_CR16","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1124\/dmd.122.000885","volume":"50","author":"L Lin","year":"2022","unstructured":"Lin L, Wright MR, Hop C, Wong H (2022) Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib. Drug Metab Dispos 50(9):1170\u20131181. https:\/\/doi.org\/10.1124\/dmd.122.000885","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4935_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11030-021-10186-7","volume":"25","author":"H Mamada","year":"2021","unstructured":"Mamada H, Iwamoto K, Nomura Y, Uesawa Y (2021) Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans. Mol Divers 25(3):1261\u20131270. https:\/\/doi.org\/10.1007\/s11030-021-10186-7","journal-title":"Mol Divers"},{"issue":"2","key":"4935_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1124\/dmd.120.000202","volume":"49","author":"N Murad","year":"2021","unstructured":"Murad N, Pasikanti KK, Madej BD, Minnich A, McComas JM, Crouch S, Polli JW, Weber AD (2021) Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds. Drug Metab Dispos 49(2):169\u2013178. https:\/\/doi.org\/10.1124\/dmd.120.000202","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"4935_CR19","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","volume":"32","author":"MV Varma","year":"2015","unstructured":"Varma MV, Steyn SJ, Allerton C, El-Kattan AF (2015) Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). Pharm Res 32(12):3785\u20133802. https:\/\/doi.org\/10.1007\/s11095-015-1749-4","journal-title":"Pharm Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04935-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04935-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04935-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:03:14Z","timestamp":1786543394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04935-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4935"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04935-4","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L., J.S.T, K.A.S., and J.R. are inventors on patents and\/or patent applications related to mithramycin derivatives with anticancer activity. These intellectual property rights are assigned to the University of Kentucky. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}